Trial Profile

Phase III trial of bevacizumab biosimilar (ONS-1045) in patients with cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 22 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary)
Indications Cancer
Focus Registrational; Therapeutic Use
Sponsors Outlook Therapeutics

Most Recent Events

14 Feb 2018 According to an Oncobiologics media release, Company expects to initiate this trial in 2019, and submit application to FDA in 2021.
20 Apr 2015 New trial record
15 Apr 2015 This trial, the first in a global phase III programme, is expected to be initiated in the fourth quarter of 2015, after pharmacokinetic data from a pivotal pharmacokinetic study have been reported, according to an Oncobiologics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com